Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.

These therapeutics generated 4 Investigational New Drug (IND) applications and over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.

Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need. This transaction represents the key next stage in the development of these promising assets.

The deal included an upfront payment as well as typical success-based milestones and royalties. Specific financial terms of the deal were not disclosed.

"We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry," stated Dr. Sam Clark, Terran's Founder and CEO.

About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing of number of late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact

Investor Relations:
[email protected]

Media:
[email protected]

Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg 


ข่าวTerran Biosciences+o:editorวันนี้

Seafood from Norway launches the "Salmon Saturday" campaign, encouraging Thais to enjoy Salmon with their families while introducing a new trend of eating Salmon every Saturday

Seafood from Norway is introducing the 'Salmon Saturday' campaign for the first time, based on the fact that Thai love to eat Salmon whether at home or dining out, with weekends, especially Saturdays, being the peak time for enjoying delicious and healthy Norwegian Salmon every Saturday with their families, friends, or loved ones. The campaign partners with leading restaurants and retail partners nationwide to offer special promotions, inviting Salmon lovers to enjoy in various styles. Known for

ฮอนด้า ประกาศแต่งตั้ง "โคจิ อิวานามิ" ดำร... ฮอนด้า ประกาศแต่งตั้ง "โคจิ อิวานามิ" ดำรงตำแหน่งประธานกรรมการบริหารและซีอีโอ — ฮอนด้า ประกาศแต่งตั้ง "โคจิ อิวานามิ" ดำรงตำแหน่งประธานกรรมการบริหารและซีอ...

Iwanami Appointed President & CEO of Hond... Iwanami Appointed President & CEO of Honda Thailand — Iwanami Appointed President & CEO of Honda Thailand, Set to Deepen Emotional Connection and Cust...

BEARHOUSE ฉลอง 6 ปี ปล่อยอัปเดต Patch 3.2... BEARHOUSE ฉลอง 6 ปีแห่งความสุข พร้อมเซอร์ไพรส์พิเศษที่ให้ความสุขแบบไม่มีสิ้นสุด! — BEARHOUSE ฉลอง 6 ปี ปล่อยอัปเดต Patch 3.2 เพิ่มน้ำ +37.5% เพิ่มเนื้อผลไ...

The highly anticipated Heaven747 Songkran... Heaven747 Songkran Festival 2025 Marks the Start of a New Era for New Poipet, Cambodia — The highly anticipated Heaven747 Songkran Festival 2025 made hist...

เทอร์แรน ไบโอซายน์ส เซ็นสัญญากับซาโนฟี่ ขอสิทธินำยารักษาระบบประสาทส่วนกลางไปพัฒนาต่อ

เทอร์แรนเตรียมเดินหน้าพัฒนายารักษาระบบประสาทส่วนกลางที่ซาโนฟี่กำลังศึกษาในเฟส 3 รวม 2 กลุ่ม ครอบคลุมสิทธิ์แต่เพียงผู้เดียวทั่วโลกในการพัฒนาและวางจำหน่ายสำหรับการใช้งานทุกประเภท เทอร์แรน ไบโอซายน์ส (Terran Biosciences...

Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics Transaction includes worldwide exclusive rights for development and commercialization in all fields of use Terran Biosciences,...